Sign in Subscribe
Cable television broadcasting industry

Stock Movers of Note: TiVo, Comcast, and More

Strategic Insights

— 1 min read

TiVo Inc. and Comcast have reached a significant agreement, making the TiVo service and advertising capability widely available to Comcast customers in the majority of the company's markets. This development has led to a substantial increase in TiVo's stock price. In other notable moves, Medicore, Inc. is merging with Dialysis Corporation of America, Celeritek, Inc. is selling its gallium arsenide semiconductor components business to Mimix Broadband, Inc., and Genta Incorporated has received Orphan Drug designation from the FDA for its treatment LR3001.

Key Takeaways:

  • TiVo Inc. (Nasdaq: TIVO) has reached a 57.70% increase in stock price after agreement with Comcast (Nasdaq: CMCSA) to make TiVo service and advertising capability widely available.
  • Medicore, Inc. (Nasdaq: MDKI) will merge with Dialysis Corporation of America (Nasdaq: DCAI), resulting in a 45.85% increase in stock price.
  • Celeritek, Inc. (Nasdaq: CLTK) is selling its assets to Mimix Broadband, Inc. for $2.8 million in cash, resulting in a 40.85% increase in stock price.
  • Genta Incorporated (Nasdaq: GNTA) has received Orphan Drug designation from the FDA for LR3001, a treatment for chronic myelocytic leukemia, resulting in a 6.56% increase in stock price.
  • Medicore, Inc. and Dialysis Corporation of America's merger is worth noting, as it will create a significant player in the healthcare industry.
  • Celeritek, Inc.'s sale of its assets to Mimix Broadband, Inc. highlights the trend of consolidation in the technology industry.
  • Genta Incorporated's Orphan Drug designation is a significant breakthrough in the development of treatments for rare diseases.

Statistics:

  • TiVo Inc.'s stock price has increased by 57.70% after the agreement with Comcast.
  • Medicore, Inc.'s stock price has increased by 45.85% after merging with Dialysis Corporation of America.
  • Celeritek, Inc.'s stock price has increased by 40.85% after selling its assets to Mimix Broadband, Inc.
  • Genta Incorporated's stock price has increased by 6.56% after receiving Orphan Drug designation from the FDA.
  • The Orphan Drug designation is a critical milestone in the development of LR3001, which could potentially improve treatment options for patients with chronic myelocytic leukemia.

Sources:

  • StreetInsider.com: Stock Movers of Note 03/15 (C)1994-2005 M2 COMMUNICATIONS LTD
  • TiVo Inc. (Nasdaq: TIVO)
  • Comcast (Nasdaq: CMCSA)
  • Medicore, Inc. (Nasdaq: MDKI)
  • Dialysis Corporation of America (Nasdaq: DCAI)
  • Celeritek, Inc. (Nasdaq: CLTK)
  • Mimix Broadband, Inc.
  • Genta Incorporated (Nasdaq: GNTA)
  • FDA

Read more